HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Monograph Modernization Initiative Looks To Close OTC Quality Loopholes

This article was originally published in The Tan Sheet

Executive Summary

A collaboration among industry, FDA and U.S. Pharmacopeia aims to address what FDA sees as a lack of insight into the quality and purity of OTC monograph drugs

You may also be interested in...

CHPA Offers OTC Testing, Degradant Standards For Monograph Modernization

The Consumer Healthcare Products Association looks to shape U.S. Pharmacopeia's revision of monographs for OTC drug ingredients and products with proposals for the standard-setting organization's monograph modernization process.

In Brief

FDA reverses on OTC PPI fracture risk

Senate Bill Expands FDA's OTC Manufacturing Oversight

Legislation introduced in the Senate to give FDA mandatory recall authority for all drugs would bar the agency from considering a drug's prescription status when assessing risk to prioritize inspections

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts